Log In
Print this Print this

oprelvekin (Neumega, rhIL-11)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionRecombinant human interleukin-11 (IL-11)
Molecular Target Interleukin-11 (IL-11) receptor
Mechanism of ActionInterleukin-11 (IL-11) receptor agonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationThrombocytopenia
Indication DetailsPrevent recurrent severe chemotherapy-induced thrombocytopenia; Prevent severe thrombocytopenia; Prevent severe thrombocytopenia due to myelosuppressive chemotherapy; Restore platelets after chemotherapy; Treat chemotherapy-induced platelet deficiency; Treat chemotherapy-induced thrombocytopenia; Treat thrombocytopenia; Treat thrombocytopenia (low platelet counts) after chemotherapy for solid tumors or lymphoma; Treat thrombocytopenia in hepatitis C patients
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today